Capitalizing Innovation and Reversing It: Mandatory R&D Tax Amortization, Cash-Tax Drains, and Corporate Investment Across the 2022–2025 U.S. Policy Cycle

When corporate tax statutes defer immediate expensing of intangible investment into multi-year amortization and subsequently restore expensing, user-cost theory predicts a two-sided liquidity pulse concentrated among taxable research-intensive firms. We evaluate this timing-wedge hypothesis across the 2022–2024 mandatory capitalization of research and experimental expenditures under Internal Revenue Code Section 174 and the 2025 domestic expensing restoration under Section 174A. From 4,662 U.S.-incorporated non-financial, non-utility annual corporate filers (40,292 annual periods observed in filings submitted through November 12, 2026), we construct an accounting-corroborated continuous research panel of 586 firms (4,688 firm-years) that eliminates reverse-merger balance-sheet mismatches, alongside an 802-firm date-matched comparison panel. Among firms with positive pre-policy operating income (N = 961, 153 firms, 12 two-digit industries), the conditional slope of net cash income taxes over beginning assets on pre-policy research intensity is +0.0527 during mandatory amortization (SE = 0.0519; restricted wild cluster bootstrap p = 0.2852) and +0.0140 during initial 2025 restoration (SE = 0.0417; bootstrap p = 0.7021), yielding an imprecise reversal contrast of -0.0387 (SE = 0.0357; bootstrap p = 0.2112); omitting a single extreme-hat-value medical-instruments issuer raises the amortization slope to +0.1043 (SE = 0.0219; bootstrap p = 0.0660) and the 2025 slope to +0.0509, while revenue-scaled (+0.1326, bootstrap p = 0.012) and pre-refund gross (+0.1094, bootstrap p = 0.032) cash-tax slopes are positive. Exact unclipped accounting decompositions show that the cash-less-accrued tax wedge widens by +0.1444 in amortization and +0.1575 in 2025 (baseline winsorized slopes +0.1305, bootstrap p = 0.2425, and +0.1329, bootstrap p = 0.0208, or +1.31 and +1.33 percentage points of assets per 10-percentage-point higher research intensity), reflecting positive contemporaneous-income-adjusted cash-tax slopes (+0.0916 and +0.0938) alongside post-2020 earnings mean reversion in book tax accruals, whereas current federal tax expense exhibits a triple-difference reversal contrast of -0.0557 (SE = 0.0194; bootstrap p = 0.020; N = 1,906). Post-2021 research (-0.1682) and capital-expenditure (-0.0324) slopes follow pre-policy upward trends, attenuate under a 2016–2017 exposure anchor (-0.0503, N = 1,216), and show a positive low-cash research interaction (+0.2419, bootstrap p = 0.044), consistent with consolidated jurisdictional aggregation and mid-year enactment timing attenuating observable statutory tax-shield shocks.

Authors

Publication Details

Journal
Commentary and Critique
Published
2026-11-13
DOI
https://doi.org/10.62432/appe.cc.2026.12.51
Primary Topic
Corporate Taxation and Avoidance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Capitalizing Innovation and Reversing It: Mandatory R&D Tax Amortization, Cash-Tax Drains, and Corporate Investment Across the 2022–2025 U.S. Policy Cycle

Natalie Goh, Farhod Rakhimov, Pavel Rogovtsev
1 links
Commentary and Critique
Corporate Taxation and Avoidance
article

Capitalizing Innovation and Reversing It: Mandatory R&D Tax Amortization, Cash-Tax Drains, and Corporate Investment Across the 2022–2025 U.S. Policy Cycle

Natalie Goh, Farhod Rakhimov, Pavel Rogovtsev
article en

Abstract

When corporate tax statutes defer immediate expensing of intangible investment into multi-year amortization and subsequently restore expensing, user-cost theory predicts a two-sided liquidity pulse concentrated among taxable research-intensive firms. We evaluate this timing-wedge hypothesis across the 2022–2024 mandatory capitalization of research and experimental expenditures under Internal Revenue Code Section 174 and the 2025 domestic expensing restoration under Section 174A. From 4,662 U.S.-incorporated non-financial, non-utility annual corporate filers (40,292 annual periods observed in filings submitted through November 12, 2026), we construct an accounting-corroborated continuous research panel of 586 firms (4,688 firm-years) that eliminates reverse-merger balance-sheet mismatches, alongside an 802-firm date-matched comparison panel. Among firms with positive pre-policy operating income (N = 961, 153 firms, 12 two-digit industries), the conditional slope of net cash income taxes over beginning assets on pre-policy research intensity is +0.0527 during mandatory amortization (SE = 0.0519; restricted wild cluster bootstrap p = 0.2852) and +0.0140 during initial 2025 restoration (SE = 0.0417; bootstrap p = 0.7021), yielding an imprecise reversal contrast of -0.0387 (SE = 0.0357; bootstrap p = 0.2112); omitting a single extreme-hat-value medical-instruments issuer raises the amortization slope to +0.1043 (SE = 0.0219; bootstrap p = 0.0660) and the 2025 slope to +0.0509, while revenue-scaled (+0.1326, bootstrap p = 0.012) and pre-refund gross (+0.1094, bootstrap p = 0.032) cash-tax slopes are positive. Exact unclipped accounting decompositions show that the cash-less-accrued tax wedge widens by +0.1444 in amortization and +0.1575 in 2025 (baseline winsorized slopes +0.1305, bootstrap p = 0.2425, and +0.1329, bootstrap p = 0.0208, or +1.31 and +1.33 percentage points of assets per 10-percentage-point higher research intensity), reflecting positive contemporaneous-income-adjusted cash-tax slopes (+0.0916 and +0.0938) alongside post-2020 earnings mean reversion in book tax accruals, whereas current federal tax expense exhibits a triple-difference reversal contrast of -0.0557 (SE = 0.0194; bootstrap p = 0.020; N = 1,906). Post-2021 research (-0.1682) and capital-expenditure (-0.0324) slopes follow pre-policy upward trends, attenuate under a 2016–2017 exposure anchor (-0.0503, N = 1,216), and show a positive low-cash research interaction (+0.2419, bootstrap p = 0.044), consistent with consolidated jurisdictional aggregation and mid-year enactment timing attenuating observable statutory tax-shield shocks.

Commentary and CritiqueVol. 12
Corporate Taxation and Avoidance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon